Hepatobiliary Neoplasia 2. Enhancing Treatment
Nov
2026
Description
This session reviews systemic and locoregional treatment strategies for advanced HCC, including network meta-analyses of combination therapies, AI-assisted tumor board support, and multidisciplinary decision-making outcomes.
Presentations
2:00 PM
- 2:15 PM
Convention Center - Bluebird Ballroom 1C
Augmenting the Tumor Board: A Multi-Agent AI Pipeline for Liver Cancer Treatment Recommendations
Richie Manikat, MD | Abstract Presenter
2:15 PM
- 2:30 PM
Convention Center - Bluebird Ballroom 1C
Etiology Dissociates the Causes of Death After Liver Transplant for Hepatocellular Carcinoma: A Competing-Risks Analysis of 12,001 DAA-Era Recipients
Shilpa Junna, MD | Abstract Presenter
2:30 PM
- 2:45 PM
Convention Center - Bluebird Ballroom 1C
Comparative Efficacy and Safety of First-Line Systemic Combinations in Unresectable Hepatocellular Carcinoma (uHCC): A Bayesian Network Meta-Analysis of 11 Phase III Trials
Rahul Falodia, MBBS | Abstract Presenter
2:45 PM
- 3:00 PM
Convention Center - Bluebird Ballroom 1C
Sequential Transarterial Radioembolization and Atezolizumab plus Bevacizumab Improves Survival in Advanced Hepatocellular Carcinoma: A Propensity Score-Matched Analysis
Yunmi Ko, MD | Abstract Presenter
3:00 PM
- 3:15 PM
Convention Center - Bluebird Ballroom 1C
Magnetic Particle Imaging Guides Dosing of ID3-Enhanced, TGFBR2-Deleted iPSC-Derived CAR Macrophages for Hepatocellular Carcinoma
TUO SHAO, PhD | Abstract Presenter
3:15 PM
- 3:30 PM
Convention Center - Bluebird Ballroom 1C
Targetable IL1B-Driven Myeloid Inflammation Mediates Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Wenying Qiao, MD | Abstract Presenter
